December 6, 2022Open Access

Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up

Key Points

Key points are not available for this paper at this time.

Abstract

With ClinicalTrials.gov NCT02256436 (KEYNOTE-045); https://clinicaltrials.gov/ct2/show/NCT02256436 and NCT02335424 (KEYNOTE-052); https://clinicaltrials.gov/ct2/show/NCT02335424.

KI fragen

Bookmark

View Full Paper

Cite This Study

Balar et al. (Tue,) studied this question.

synapsesocial.com/papers/69e005be93e101b251e9c6e4 https://doi.org/https://doi.org/10.1016/j.annonc.2022.11.012

KI fragen

Bookmark

View Full Paper